CA
NZ
UK
AU
IND
US
Key HighlightsFlux Power (NASDAQ:FLUX) indicated USD 0.3035 pre-market on November 10, 2026, down 15.9% from a calculated prior close of USD 0.3610, a level that implies aMarket Valuenear USD 6.56 million.Fiscal first-quarterRevenuereported November 3, 2026 was USD 6.758 million, down 48.7% from USD 13.175 …
No catalyst for the decline was identified in published coverage. The most recent company news, around November 9, 2026, was a set of Letters of Intent for commercial collaborations in Malaysia on sovereign border management and security. Earlier, about nine months ago, the company …
The quarter showed operating leverage.Net Incomerose to USD 7.0 million from USD 0.8 million, and adjusted EBITDA more than doubled to USD 11.5 million from USD 5.3 million, even asResearch and Developmentspending rose to USD 11.0 million and selling, general and administrative costs increased …
No catalyst for the move was confirmed in published coverage. Relevant background: on September 16, 2026 the company highlighted the first patient treated in its IDE study of the vCLAS Ultra system for ventricular tachycardia, and about September 23, 2026 it announced a strategic …
No catalyst for Tuesday's decline was identified in published coverage. The company's recent record is relevant: a 1-for-25 reverse split took effect March 23, 2026; fiscal 2025 results came on April 10, 2026; a registered direct offering of up to USD 12.0 million was …
The result gives the company a path into a large market where patients have run out of options, and it validates the drug in a disease where FcRn blockers had not been proven. A randomisedWithdrawaldesign is a demanding test, because it measures whether patients …
The pressure is tied to a financing and a listing problem, not to a new operating release. The prospectus describes a USD 13.5 million underwritten offering of units with warrants exercisable at USD 6.80, an 8.0% underwriter fee plus USD 125,000 of legal fees, …
The strength and consistency of the data across endpoints reduced the main uncertainty around the programme of Vir Biotechnology (NASDAQ:VIR). Results in cirrhotic patients, the hardest group to treat, were as strong as in the overall population, with 85% achieving undetectable virus against 73% …
No company release, filing, trial result, offering or analyst action dated November 9 or November 10, 2026 was identified in published coverage after two searches, so no catalyst identified is the accurate statement. The most recent dated items found were the March 18, 2026 …
The scale of the fall suggests investors had priced in a stronger efficacy signal. A 33% confirmed response rate is respectable for a late-line population, but the comparison that matters is with paclitaxel alone and with other targeted options, and a single-arm study of …
Please wait processing your request...